Niklas Loman

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Andrew Tutt, Mark E. Robson, Judy E. Garber et al. · The Lancet · 2010 · 1.6K citations

Medicine, Oncology, Pharmacotherapy +13

A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population

Antonis C. Antoniou, Xianshu Wang, Zachary S. Fredericksen et al. · Nature Genetics · 2010 · 342 citations · Full text

Medicine, Genetics, Oncology +17

Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer

Christopher A. Maxwell, Javier Benítez, Laia Gómez‐Baldó et al. · PLoS Biology · 2011 · 193 citations · Full text

Medicine, Genetics, Oncology +17

Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women

Timothy R. Rebbeck, Tara M. Friebel, Nandita Mitra et al. · Breast Cancer Research · 2016 · 73 citations · Full text

Life Sciences, Genetics, Molecular Genetics +11

VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

Andrew Tutt, John J. Garber, R.D. Gelber et al. · Annals of Oncology · 2022 · 39 citations · Full text

Medicine, Oncology, Pharmacotherapy +17